Specifically, the FDA recently approved Arexvy, the world’s first vaccine to fight RSV in adults aged 60 and older. According to its manufacturer GSK, the single shot provides long-term ...
Pharmaceutical giant GSK has won a key part of the regulatory approval needed to roll out its vaccine for respiratory syncytial virus (RSV) to adults aged 50 to 59. The US Food and Drug ...
GSK (GSK) added that the ruling has no impact on its ability to launch and market its RSV vaccine Arexvy in markets around ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback